Janssen Pharmaceuticals Inc.

03/26/2024 | Press release | Distributed by Public on 03/26/2024 09:47

Johnson & Johnson’s nipocalimab granted U.S. FDA Fast Track designation to reduce the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in alloimmunized pregnant adults

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.